八位董监高集体降薪背后，硕世生物称要“先活下去”

Core Viewpoint - The company is facing significant operational challenges, leading to a voluntary salary reduction among its senior management as a gesture of solidarity during tough times [2][4][5]. Group 1: Company Performance - In the first half of 2025, the company reported a revenue of 176 million, a year-on-year decrease of 1.05%, and a net profit attributable to shareholders of 3.99 million, down 86.35% [2][3]. - The decline in performance is attributed to two main factors: the impact of centralized procurement policies leading to price pressure on products, and an increase in the value-added tax rate for self-produced testing reagents to 13%, which reduced gross margins [3][6]. Group 2: Management Response - Eight senior executives, including the honorary chairman and the chairman, announced voluntary salary reductions ranging from 5% to 50%, effective from August 15, 2025 [2][4]. - The total pre-tax compensation for these executives exceeded 10 million prior to the salary cuts, indicating a significant financial commitment to support the company during its struggles [4][5]. Group 3: Industry Context - The in vitro diagnostic (IVD) industry is experiencing widespread challenges, with many companies facing profit declines or losses due to similar pressures from centralized procurement and fluctuating market demand [6][7]. - The company plans to focus on several strategic areas, including increasing R&D investment, enhancing smart manufacturing, and deepening internationalization, although immediate improvements are uncertain [6][7]. Group 4: Future Outlook - The company remains optimistic about its overseas business potential, although current contributions are small and significant growth is not expected in the short term [6][7]. - Industry experts suggest that technological upgrades and structural adjustments are essential for overcoming current challenges, with a shift towards precision and intelligent diagnostics anticipated in the future [7].